Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com

Richard H. Bagger, a director at Tonix Pharmaceuticals Holding Corp. (), recently acquired shares of the company’s common stock totaling $12,600.

According to a recent filing, Mr. Bagger purchased 1,000 shares on August 20, 2026, at a price of $12.60 per share. Following this transaction, Mr. Bagger directly holds 1,000 shares of the company’s common stock.The purchase comes as TNXP trades at $12.55, with the stock showing a strong return over the last month according to InvestingPro analysis. The company carries a market cap of $215 million and is currently trading below its Fair Value, placing it among undervalued stocks. Investors seeking deeper insights can access TNXP’s comprehensive Pro Research Report, one of 1,400+ available on InvestingPro.

In other recent news, Tonix Pharmaceuticals reported impressive second-quarter results, beating analysts’ expectations on both earnings and revenue. The company posted an adjusted earnings per share of -$2.44, outperforming the forecasted -$2.71, and generated revenue of $13.54 million, nearly doubling the anticipated $6.96 million. This surge was largely driven by the strong sales of Tonmya, which saw net sales almost triple quarter-over-quarter to $11 million. Raymond James responded to these developments by raising its price target for Tonix Pharma to $27.00 from $26.00, while maintaining a Strong Buy rating. The firm highlighted the robust sales performance of Tonmya as a positive indicator for the product’s market launch. Despite these achievements, investors showed concern over the company’s ongoing losses, increasing expenses, and cash runway extending only into early 2027. These recent developments reflect significant progress for Tonix Pharmaceuticals, but also underscore the challenges the company faces moving forward.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.